Array BioPharma, Bristol-Myers Squibb collaborating to investigate metastatic colorectal cancer treatment — 4 key notes

Array BioPharma and Bristol-Myers Squibb Co. are investigating the safety, tolerability and efficacy of Array's investigational MEK inhibitor binimetinib when used with Bristol Myers Squibb's Opdivo and Opdivo + Yeroy regime.

Researchers intended to see how the treatments will affect metastatic colorectal cancer patients with microsatellite stable tumors.

Here's what you should know.

1. The companies are collaborating on a phase 1/2 study.

2. The results will determine recommended dose regimens. Researchers are hoping the treatments produce preliminary anti-tumor activity.

3. The companies want to begin the study in late 2017.

4. The companies will use the study results to propel further research.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast